Neuropace Inc (NPCE) Stock AnalysisNPCEStock AnalysisNeuropace Inc

NeuroPace, Inc. is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. The Company's RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders. The Company's RNS System includes its RNS neurostimulator, its cortical strip leads and depth leads, and its Patient Remote Monitor, as well as other implantable and non-implantable accessories. The Company's product offerings also include Physician Tablet, Patient Data Management System (PDMS) and nSight Platform, which facilitate ongoing patient monitoring and streamline patient support. The PDMS is an online database. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Neuropace Inc is a good buy right now due to its current price of $14.41 being significantly below analyst targets, with Mizuho projecting a price of $22, indicating a potential upside of over 52%. Additionally, the company's gross margin has improved to 82.83% in Q2 2026, showcasing strong profitability potential. However, the main risk is the FDA denial for the RNS system expansion, which could impact revenue growth projections, particularly as the company anticipates a revenue range of $99 million to $101 million for 2026, which could be affected by this setback.